- Supported exchanges /
- ST /
- CRNO-B.ST
Cereno Scientific AB Series B (CRNO-B ST) stock market data APIs
Cereno Scientific AB (publ), clinical stage biotechnology company, develops therapeutics to treat cardiovascular and rare diseases worldwide. The company's lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic, and antithrombotic properties. Its preclinical drug candidates comprise CS585 and CS014 that is in pre clinical stage for the treatment of cardiovascular diseases. The company has a collaboration agreement with the University of Michigan for the preclinical development program of CS585 and CS014, are preclinical drug candidate for cardiovascular diseases; and Abbott for use of CardioMEMS HF System, as well as collaboration with the Pulmonary and Vascular Research Institute (PVRI). Cereno Scientific AB (publ) was founded in 2012 and is headquartered in Gothenburg, Sweden.
Cereno Scientific AB Series B Financial Data Overview
| 4.678 | |
| 5.39 | |
| - | |
| 5.335 | |
| 4.4 | |
| 3.405-9.5 | |
| 1 380 M | |
| 281 M | |
| 68 724 K | |
| -0.08 | |
| 0.349 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Cereno Scientific AB Series B Fundamental Data is available in our Financial Data APIs
- Net Revenue 68 724 K
- EBITDA -62 375 136
- Earnings Per Share -0.31
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Cereno Scientific AB Series B Earnings via APIs
- Latest Release 2024-06-30
- EPS/Forecast -0.05
Get Cereno Scientific AB Series B End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
